Carolyn C. Tang

CIK: 0001836662

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (33.3%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RCUS

Arcus Biosciences, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

RCUS
Arcus Biosciences, Inc.
Jun 11, 2026
Exercise(M)
Direct
34.1K shares at avg. $2.57$88K
RCUS
Arcus Biosciences, Inc.
Jan 23, 2026
Award(A)
Direct
24K shares-
RCUS
Arcus Biosciences, Inc.
Dec 17, 2025
Sale(S)
Direct
6.8K shares at avg. $22.16$151K
RCUS
Arcus Biosciences, Inc.
Dec 16, 2025
Sale(S)
Direct
7.7K shares at avg. $21.88$168K
RCUS
Arcus Biosciences, Inc.
Jan 23, 2025
Award(A)
Direct
37K shares-
RCUS
Arcus Biosciences, Inc.
Dec 15, 2024
Tax Payment(F)
Direct
11.3K shares at avg. $16.08$182K

		Type	Shares	Price		Ownership
Jun 11, 2026	RCUS Arcus Biosciences, Inc.	Exercise(M)	34,090	$2.57	$87,748	Direct
Jan 23, 2026	RCUS Arcus Biosciences, Inc.	Award(A)	24,000	-	$0	Direct
Dec 17, 2025	RCUS Arcus Biosciences, Inc.	Sale(S)	6,810	$22.16	$150,906	Direct
Dec 16, 2025	RCUS Arcus Biosciences, Inc.	Sale(S)	7,658	$21.88	$167,590	Direct
Jan 23, 2025	RCUS Arcus Biosciences, Inc.	Award(A)	37,000	-	$0	Direct
Dec 15, 2024	RCUS Arcus Biosciences, Inc.	Tax Payment(F)	11,339	$16.08	$182,331	Direct

1-6 of 6 transactions

About Tang Carolyn C.

Tang Carolyn C. (SEC CIK 0001836662) files insider reports with the SEC as General Counsel of Arcus Biosciences, Inc. (RCUS).

Signal8 holds 5 ownership filings by Tang Carolyn C., all Form 4s, filed between Dec 17, 2024 and Jun 12, 2026. Those filings report 6 transactions, from Dec 15, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tang Carolyn C.'s filings is in HAYWARD, CA.

Recent filings by Tang Carolyn C.

Jun 11, 2026: Option exercise of RCUS shares (Form 4, code M).
Jan 23, 2026: Grant or award of RCUS shares (Form 4, code A).
Dec 17, 2025: Open-market sale of RCUS shares (Form 4, code S).
Dec 16, 2025: Open-market sale of RCUS shares (Form 4, code S).
Jan 23, 2025: Grant or award of RCUS shares (Form 4, code A).

Other insiders filing for Arcus Biosciences, Inc. (RCUS)

Azoy Alexander, Chief Accounting Officer
Jaen Juan C., President
Lambert Nicole, Director
Machado Patrick, Director
KANEKO YASUNORI, Director
Lacey David L., Director

How to read Form 4 transaction codes